• MBHB Logo 2McDonnell Boehnen Hulbert & Berghoff LLP will be offering a live webinar entitled "The Defend Trade Secrets Act at (Almost) One" on April 18, 2017 from 10:00 am to 11:15 am (CT).  In this presentation, MBHB attorney and Patent Docs contributor Joshua R. Rich will discuss the following topics:

    • What are the provisions of the DTSA, and how do they differ from state laws?
    • How have parties used the DTSA in litigation?
    • How have courts addressed DTSA claims in litigation?
    • What other significant trade secret events have occurred since the DTSA was enacted?

    While there is no fee to participate, attendees must register in advance.  Those wishing to register can do so here.  CLE credit is pending for the states of California, Illinois, New Jersey, New York, North Carolina, and Virginia.

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "IPR Estoppel in District Court: How Wide?" on March 29, 2017 from 2:00 to 3:00 pm (ET).  Jon Gurka of Knobbe, Martens, Olson & Bear LLP, Hon. Faith Hochberg of Hochberg ADR, and Thad Kodish of Fish & Richardson PC will analyze the application of estoppel for invalidity arguments in district court and the PTAB for both patent owners and petitioners, and offer tactics on how both can best navigate the legal uncertainties.

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Washington College of LawAs part of its ongoing Supreme Court series, the American University Washington College of Law Program on Information Justice & Intellectual Property will be hosting a post-argument discussion on the TC Heartland LLC v. Kraft Foods Group Brands LLC case from 4:15 to 5:45 pm (Eastern) on March 27, 2017 at the American University Washington College of Law in Washington, DC.  The panel discussion will be moderated by Prof. Michael Carroll, American University Washington College of Law, with a panel consisting of Professor Jonas Anderson, American University Washington College of Law; James Dabney, Hughes Hubbard & Reed LLP, Counsel for Petitioner; Brian Burgess, Goodwin Proctor LLP, Counsel for Respondent; and Professor Megan La Belle, Catholic University of America School of Law, representing Professors of Patent Law and Civil Procedure on amicus brief.

    Additional information about the post-argument discussion, including registration/CLE information, can be found here.

  • Federal Circuit Bar AssociationBaylor Law School and the Federal Circuit Bar Association (FCBA) will be offering a program entitled "Patent Litigation: Trial and Appellate Issues and Trends" on April 7, 2017 from 10:30 am to 2:35 pm (EST) at the Hyatt Regency Washington on Capitol Hill in Washington, DC.  The program will include presentations on the following topics:

    • Managing Complex IP Litigation: Case Management – Effective and Efficient Litigation
    • Case Management and Abusive Litigation
    • Developments in IP Adjudication – Perceptions of the Appellate Bench

    Baylor Law SchoolThose interested in registering for the program, can do so here.  Additional information regarding the program can be found here.

  • Strafford #1Strafford will be offering a webinar/teleconference entitled "Markush Claims in Pharma/Chemical Patent Prosecution and Litigation: Leveraging Federal Court Guidance — Constructing Group Claims, Navigating Comprising and Consisting of, Avoiding Improper Rejections" on April 6, 2017 from 1:00 to 2:30 pm (EDT).  Thomas L. Irving of Finnegan Henderson Farabow Garrett & Dunner, Laura A. Labeots of Husch Blackwell, and Amanda K. Murphy, Ph.D., of Finnegan Henderson Farabow Garrett & Dunner will provide guidance to patent counsel on Markush claims in the prosecution and litigation of patents, review the original case, Ex Parte Markush, and other key cases, and discuss the ongoing debate about what Markush groups mean, how to best handle patent prosecution, and offer guidance on Markush practice.  The webinar will review the following issues:

    • What lessons can be learned from recent Federal Circuit decisions?
    • What steps can patent counsel take to avoid indefiniteness, double inclusion and other issues that arise with Markush claims?
    • What strategies should patent counsel employ to reduce the likelihood of an improper Markush rejection?

    The registration fee for the webinar is $297.  Those interested in registering for the webinar, can do so here.

  • By Andrew Williams

    Supreme Court Building #1Next week, on Monday March 27, the Supreme Court will hear oral arguments in the TC Heartland LLC v. Kraft Foods Group Brands LLC case.  This case involves the interpretation of the current patent venue statute.  And while interpreting statutory language may seem dry, the outcome of this case could have a significant impact on the so-called Patent Troll problem.  Unfortunately, it could also negatively affect all patent owners seeking to legitimately assert their patent right against infringers, regardless of how blatant the infringement is.  As a result, it is not surprising that this case has generated a significant amount of amicus interest from patent owners, trade organizations, academics, and the operating companies that are generally targets for these so-called patent trolls.

    In particular, sixteen amicus briefs were filed in support of petitioner TC Heartland, the party seeking a narrow interpretation of the statute determining which venues a patent infringement case can be brought.  These parties range from 48 internet companies, retailers, and associations (in a single brief); a brief from 61 professors of law and economics (also in a single brief); the states of Texas, Arizona, Colorado, Connecticut, Hawaii, Illinois, Iowa, Maine, Maryland, Michigan, Nebraska, North Carolina, Ohio, South Carolina, Vermont, Virginia, and Wisconsin (again, in a single brief); the ABA; and not surprisingly, the Electronic Frontier Foundation.  Of particular interest for the life sciences community, the Generic Pharmaceutical Association also filed an amicus brief in support of petitioner, in which they argued in part that the Federal Circuit's interpretation of the statute, in conjunction with its jurisdictional decision in Acorda Therapeutics Inc. v. Mylan Pharms, has worked to delay the public's access to low cost generic drugs.

    On the other hand, eleven amicus briefs were filed in support of respondent, Kraft Foods.  These parties range from 33 practicing-entity patent owners (in a single brief); eighteen individuals and organizations representing inventors and patent owners; 22 law, economics, and business professors (in a single brief); professors of patent law and civil procedure (in a separate brief); the Biotechnology Innovation Organization (BIO) and the Association of University Technology Managers (AUTM) (together in a brief); the Pharmaceutical Research and Manufacturers of America (Phrma); and Genentech, Inc.  BIO and AUTM acknowledged that their members have been the victims of so-called patent trolls, but nevertheless, a narrow interpretation of the statute would serve to unfairly disadvantage patent owners relative to accused infringers.  Genentech, for its part, pointed out the unique situations for ANDA and BPCIA litigations, including the fact that the precipitating acts of infringement are within the defendant's control.  Finally, there were also three amicus briefs in support of neither party: the American Intellectual Property Law Association (AIPLA); the General Electric Company; and the Intellectual Property Law Association of Chicago.

    This case has an interesting procedural posture.  It stems from a denial of a writ of mandamus by the Federal Circuit that arose from a denial of a motion to dismiss a case on, among other things, venue grounds.  The litigation was brought by Kraft Foods against TC Heartland in the U.S. District Court for the District of Delaware, where it is currently pending before Chief Judge Stark.  TC Heartland is incorporated in Indiana, and has its headquarters in Carmel, Indiana.  However, other than approximately 2% of its alleged infringing product ending up in Delaware, TC Heartland has alleged that it has had no other contacts with that state.

    The posture of the case is also interesting because the issue had essentially already been decided by the Federal Circuit in VE Holding Corp. v. Johnson Gas Appliance Co., 917 F.2d 1574 (Fed. Cir. 1990) case.  As such, TC Heartland's chance of success at the Federal Circuit was minimal.  However, the last time the Supreme Court considered the specific patent venue statute, in the Fourco Glass Co. v. Transmirra Products Corp., 353 U.S. 222 (1957) case, it held that the general venue statute did not override the specific patent statute.  This is essentially the result that TC Heartland is seeking in this case — that a corporation can essentially only be sued in the state in which it is incorporated.  In TC Heartland's favor, the specific patent venue statute has not changed since that time.  However, the general venue statute has changed a couple of times in the interim, which is why the Federal Circuit deviated from the Supreme Court precedent.

    The specific venue statute for patent litigation was (and is) 28 U.S.C. § 1400(b):

    Any civil action for patent infringement may be brought in the judicial district where the defendant resides, or where the defendant has committed acts of infringement and has a regular and established place of business.

    28 U.S.C. § 1400(b).  At the time of the last Supreme Court case, the general venue statute specified that:

    (c) A corporation may be sued in any judicial district in which it is incorporated or licensed to do business or is doing business, and such judicial district shall be regarded as the residence of such corporation for venue purposes.

    28 U.S.C. § 1391(c) (1952).  However, this was amended in 1988 to be more definitional:

    (c) For purposes of venue under this chapter, a defendant that is a corporation shall be deemed to reside in any judicial district in which it is subject to personal jurisdiction at the time the action is commenced.

    28 U.S.C. § 1391(c) (1988).  There was another subsequent change in the Federal Courts Jurisdiction and Venue Clarification Act of 2011, which made two changes, including expanding the applicability of the new definition to:  "all venue purposes."  It was the addition of the phrase "[f]or purposes of venue under this chapter" that convinced the Federal Circuit to veer from Supreme Court holding in VE Holding Corp., thereby making virtually every forum available to patent holders in bringing infringement actions, provided of course that the district court had personal jurisdiction over the defendant.  Of course, critics of the opinion point out that almost the exact opposite has resulted — even though any forum can be used, it is the Eastern District of Texas and the District Court of Delaware that have seen over half of the patent litigation cases.  For example, TC Heartland included a pie chart from data obtained from Lex Machina of the impact of forum shopping in 2015, which showed that more than 43% of patent infringement cases were filed in the Texas court:

    ChartIf the Supreme Court sides with TC Heartland, Patent Trolls will be curtailed from using the Eastern District of Texas as a tool for extorting settlements from accursed infringers.  Interestingly, Congress has also attempted to solve the so-called patent troll problem by, among other things, recently introducing the VENUE Act.  However, it is unlikely that any further action will be taken by that body until other more pressing matters are addressed.  It is therefore almost certain that the TC Heartland LLC v. Kraft Foods Group Brands LLC will be resolved before that happens.

  • By Donald Zuhn

    Federal Circuit SealLast week, in Bayer CropScience AG and Bayer S.A.S. v. Dow Agrosciences LLC, the Federal Circuit determined that the District Court for the District of Delaware did not abuse its discretion in determining that, under the totality of the circumstances, the case was an exceptional one, and the Federal Circuit therefore affirmed the District Court's grant of attorney fees to Dow Agrosciences LLC.

    An earlier appeal involving the same parties focused on the scope of Bayer's license to Dow's business partner M.S. Technologies, LLC ("MS Tech"), and more specifically, whether the license granted MS Tech a broad license to commercialize and sublicense the licensed technology (i.e., soybeans genetically engineered to tolerate herbicide).  Bayer's position was that it had only licensed MS Tech rights to non-commercial exploitation of the technology, and Dow countered that the Bayer-MS Tech agreement conveyed broad rights to MS Tech, including the right to commercialize the licensed technology.  The District Court agreed with Dow's interpretation of the Bayer-MS Tech agreement and granted summary judgment in Dow's favor.  The Federal Circuit affirmed that decision in Bayer CropScience AG v. Dow AgroSciences LLC, 580 F. App’x 909 (Fed. Cir. 2014) (Bayer I).

    The case was returned to the District Court, where the Court awarded Dow attorney fees pursuant to 35 U.S.C. § 285.  In characterizing that decision, the Federal Circuit explained that "[t]he district judge examined the full duration of the litigation and concluded that, in her view, Bayer's weak positions on the merits and litigation conduct supported a finding that this was an exceptional case," adding that "the district judge emphasized that 'Bayer's own witnesses as well as key documents contradicted Bayer's contorted reading of the contract'" and that "'Bayer's conduct in litigating this case in the face of evidence that contradicted its contorted reading of the Agreement was objectively unreasonable.'"

    Bayer had relied on an exception clause in the licensing agreement that granted "a worldwide, fully paid-up, exclusive license [to MS Tech] with the exception of the rights to increase, market, distribute for sale, sell and offer for sale, granted to STINE by separate agreement."  The separate agreement to Stine referenced in the exception clause concerned a non-exclusive license Bayer gave to Stine Seed Farm, Inc. Bayer contended that the exception clause carved all commercialization rights completely out of the MS Tech license, while Dow argued that the provision indicated that the MS Tech license was not exclusive with respect to the separate license rights Stine had been granted.  The District Court, however, determined that "[t]he positions Bayer took to support their contract interpretation arguments were directly contradicted by the record evidence Bayer had obtained through early discovery and Bayer should have made every effort to discover before filing suit" adding that "[h]ad Bayer done any due diligence, it would have learned that no witness supported Bayer's construction of the Agreement and this case [] should never have been filed."

    In affirming the District Court's grant of attorney fees, the Federal Circuit noted that in Octane Fitness, LLC v. ICON Health & Fitness, Inc., 134 S. Ct. 1749, 1756 (2014), the Supreme Court had clarified what constitutes an exceptional case, namely:

    [A]n "exceptional" case is simply one that stands out from others with respect to the substantive strength of a party's litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated.  District courts may determine whether a case is "exceptional" in the case-by-case exercise of their discretion, considering the totality of the circumstances.

    The Federal Circuit determined that the District Court had not abused its discretion in finding the case to be exceptional and had applied the correct legal test under § 285, examining the totality of the circumstances to determine whether the case stood out from others.  The panel opinion notes, for example, that "[o]ne Bayer executive at the time of the deal testified that Bayer did not retain commercial rights because 'it was relatively black and white certainly in my mind that we were divesting these assets,'" and that same executive further testified that "'[i]t seems incongruous that we would sell an asset to somebody, receive remuneration for the sale, and then somehow prevent the acquirer from making use of the asset he just acquired.'"

    The Federal Circuit also determined that the District Court did not abuse its discretion in concluding that Bayer failed to perform a diligent pre-suit investigation of its claims against Dow, indicating that "Bayer's own witnesses testified against its contract interpretation," and stating that "[w]e cannot say that the district court erred in reasoning that had Bayer conducted a more searching pre-suit investigation—at least of its own easily-obtainable evidence—it would have not filed suit."  The Federal Circuit therefore held that the District Court had not abused its discretion in determining that this was an exceptional case, and affirmed the District Court's grant of attorney fees.

    Bayer CropScience AG and Bayer S.A.S. v. Dow Agrosciences LLC (Fed. Cir. 2017)
    Panel: Circuit Judges Newman, Chen, and Stoll
    Opinion by Circuit Judge Stoll

  • By Kevin E. Noonan

    Supreme Court Building #2The U.S. Supreme Court overturned another Federal Circuit decision today (this one having been decided en banc by the appellate court), in SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC.  The outcome was not a surprise, at least because 1) the decision was consistent with the Court's decision in Petrella v. Metro-Goldwyn-Mayer, Inc., decided three years ago; 2) the Justices' questioning at oral argument presaged how they were thinking; and 3) it was, after all, a Federal Circuit decision.  The decision was not unanimous, however; Justice Breyer dissented, in an opinion consistent with his general suspicion regarding bad behavior by patentees and his penchant for having the Court make policy judgments that his brethren (at least in this instance) believe are within the province of Congress.

    The case arose over infringement of SCA's patent (U.S. Patent No. 6,375,646) on adult incontinence products, which First Quality contended was invalid over its own prior art patent (U.S. Patent No. 5,415,649).  Following ex parte reexamination of SCA's patent and a finding by the USPTO that the claims were patentable over First Quality's patent, SCA brought suit (about 7 years after SCA first notified First Quality regarding its allegations of infringement).  The District Court ruled by summary judgment that SCA's suit was barred by laches (an equitable doctrine that prevents a patentee from "sleeping on her rights" by undue delay in filing a patent infringement suit).  A sharply divided Federal Circuit (6-5) affirmed en banc, based on its reasoning that although Congress enacted a six-year time limitation on money damages in the statute (35 U.S.C. § 286), the provisions of 35 U.S.C. § 282, which states that "[n]oninfringement, absence of liability for infringement or unenforceability" are available as defenses, and "unenforceability" includes within its scope the equitable doctrine of laches.  One source of the division on the appellate court was the Supreme Court's intervening Petrella decision, barring laches as a defense in copyright infringement actions based on a three-year statute of limitations enacted by Congress; the majority relied on its own earlier decision in A. C. Aukerman Co. v. R. L. Chaides Constr. Co. to the contrary.

    The Supreme Court's decision (authored by Justice Alito and joined by all but Justice Breyer) vacating the Federal Circuit's affirmance was based in part on its Petrella decision, but also on the Court's analysis of the practice at law and in equity stemming from the time when these two actions were maintained separately and when they were merged in 1938.  The Court "spoke broadly" in Petrella according to the majority, so that laches was barred as a defense whenever Congress enacted an express statute of limitations (in that case, in 17 U.S.C. § 507(b)).  The reasons for the Court's Petrella decision included "separation-of-powers principles" (wherein the judiciary does not have the power to override Congressional decisions in its statutes; see, e.g., National Federation of Independent Business v. Sebelius), according to the opinion.  Specifically Justice Alito wrote:

    When Congress enacts a statute of limi­tations, it speaks directly to the issue of timeliness and provides a rule for determining whether a claim is timely enough to permit relief.  []  The enactment of a statute of limitations necessarily reflects a congressional decision that the timeliness of covered claims is better judged on the basis of a generally hard and fast rule rather than the sort of case-specific judicial determination that occurs when a laches defense is asserted.  Therefore, applying laches within a limitations period specified by Congress would give judges a "legislation­ overriding" role that is beyond the Judiciary's power.

    In addition, the Court in Petrella (and here) considered the "traditional role of laches in equity" and its interaction with legal principles like statutes of limitations.  And here, as in Petrella, the Court determined that there was no basis for the Federal Circuit's decision that laches could contradict the statute of limitations provisions of § 286.

    With regard to the traditional role of laches in equity suits, the Court opined that this doctrine was developed for situations where Congress had not specified a fixed time for bringing suit, and thus was a "gap-filling" doctrine to cure in equity what the law did not expressly provide.  When, as here, Congress has provided an express statute of limitations "there is no gap to fill" and thus no purpose for laches according to Justice Alito’s opinion.

    The Court first rejected First Quality's contention that § 286 was not a "true" statute of limitations because it "ran backwards" from the time suit is filed to limit the temporal extent of damage rather than "run[ning] forward from the time a cause of action accrues."  Then the opinion turned to the Federal Circuit's rationale regarding the relationship between § 286 and § 282, and specifically whether § 282 satisfies the qualifying phrase from § 286 that the section governs "[e]xcept as otherwise provided by law."  The Court deigned not to parse out whether § 282 provided some measure of laches as a defense; rather, Justice Alito refused to countenance interpretation of the statute to include laches as a defense that would defeat the express statute of limitations found in § 286.  This determination was supported by a survey of cases (from both before and after enactment of the Patent Act in 1952).  In rejecting the Federal Circuit's conclusion, the opinion states that "[t]he most prominent feature of the relevant legal landscape at the time of enactment of the Patent Act was the well-established general rule, often repeated by this Court, that laches cannot be invoked to bar a claim for damages incurred within a limitations period specified by Congress," citing Holmberg v. Armbrecht; United States v. Mack; and Wehrman v. Conklin; and Cross v. Allen.  None of these were patent cases, but the opinion rejects the significance of this distinction on the grounds that "[p]atent law is governed by the same common-law principles, methods of statutory interpretation, and procedural rules as other areas of civil litigation" according to the dissent in the Federal Circuit.  Justice Alito states that "nothing less than a broad and unambiguous consensus of lower court decisions could support the inference that §282(b)(1) codi­fies a very different patent-law-specific rule," and, as is the Court's wont he finds no evidence of such a patent-law-specific rule in the cases cited by either the Federal Circuit or First Quality.  These cases included those:  "decided by equity courts before 1938" ("unpersuasive for several, often overlapping reasons"; "too few to establish a settled, national consensus"); "decided by law courts before 1938" ("even if all of these cases squarely held that laches could be applied to a damages claim at law within the limitations period, they would still constitute only a handful of decisions out of the corpus of pre­1952 patent cases, and that would not be enough to over­come the presumption that Congress legislates against the background of general common-law principles"); and "decided after the merger of equity and law in 1938" ("First Quality's evidence is scant").

    Finally, the majority rejected First Quality's invitation to make its decision based on policy considerations ("we cannot overrule Congress's judgment based on our own policy views") and suggests that other doctrines (such as equitable estoppel) may provide relief.

    Justice Breyer dissented, based on many of the policy arguments made by Respondent and amici.  Unlike the majority, the Justice sees a "gap to fill," specifically when a patentee can delay to permit an infringer to develop a product in a way that maximizes infringement damages (which would constitute "harmful and unfair legal consequences").  For example, under the provisions of § 286 "a patentee, after learning of a possible in­fringement in year 1, might wait until year 10 or year 15 or year 20 to bring a lawsuit.  And if he wins, he can col­lect damages for the preceding six years of infringement."  This "gap" could permit an infringer (including an unknowing infringer according to the dissent) to "in­vest[] heavily in the development of the infringing product (of which the patentee's invention could be only a small component), while evidence that the infringer might use to, say, show the patent is invalid disappears with time."  This is particularly pernicious in circumstances where the infringer is "locked in," i.e., when "business-related circumstances make it difficult or impos­sible for the infringer to abandon its use of the patented invention."

    Besides these policy concerns, Justice Breyer believes that the 1952 Patent Act was intended merely to codify existing law, and part of that existing law includes laches.  This law included a number of cases that the Justice sets forth expressly in the dissenting opinion, including:

    Lukens Steel Co. v. American Locomotive Co. [] (CA2 1952); Chicago Pneumatic Tool Co. v. Hughes Tool Co. [] (CA10 1951); Brennan v. Hawley Prods. Co. [] (CA7 1950); Shaffer v. Rector Well Equip. Co. [] (CA5 1946); Rome Grader & Mach. Corp. v. J. D. Adams Mfg. Co. [] (CA7 1943); France Mfg. Co. v. Jefferson Elec. Co. [] (CA6 1939); Universal Coin Lock Co. v. American Sanitary Lock Co. [] (CA7 1939); Union Shipbuild­ing Co. v. Boston Iron & Metal Co. [] (CA4 1938); Gillons v. Shell Oil Co. of Cal. [] (CA9 1936); Holman v. Oil Well Supply Co. [] (CA2 1936) (per curiam); Dock & Term. Eng. Co. v. Pennsylvania R. Co. [] (CA3 1936); Banker v. Ford Motor Co. [] (CA3 1934); Westco-Chippewa Pump Co. v. Delaware Elec. & Supply Co. [] (CA3 1933); Window Glass Mach. Co. v. Pittsburgh Plate Glass Co. [] (CA3 1933); Dwight & Lloyd Sintering Co. v. Greenawalt [] (CA2 1928); George J. Meyer Mfg. Co. v. Miller Mfg. Co. [] (CA7 1928); Wolf Mineral Process Corp. v. Minerals Separation N. Am. Corp. [] (CA4 1927); Cummings v. Wilson & Willard Mfg. Co. [] (CA9 1925); Ford v. Huff [] (CA5 1924); Wolf, Sayer & Heller, Inc. v. United States Slicing Mach. Co. [] (CA7 1919); A. R. Mosler & Co. v. Lurie [] (CA2 1913); Safety Car Heating & Lighting Co. v. Consolidated Car Heating Co. [] (CA2 1909) (per curiam); Richardson v. D. M. Osborne & Co. [] (CA2 1899); and Woodmanse & Hewitt Mfg. Co. v. Williams [] (CA6 1895).

    To the majority's rejoinder that these cases "prove[] nothing" because they are decisions from courts of equity, the Justice says "Good reply But no cigar" because:  in 1897, Congress enacted a limited statute of limitations in patent cases that could be used against claims brought in equity courts; in 1870, Congress gave equity courts the power to award damages in patent cases; Congress recognized that patent cases were brought (at that time) in courts of equity; and finally that in the (admittedly) few cases pre-merger that considered whether laches could bar suits at law, those courts held that they could.  And those cases relied upon by the majority to the contrary were not patent cases, Justice Breyer notes, and thus "do not prevent Congress from enacting a statute that, recognizing patent litigation's history, combines a statute of limitations with a laches defense," which in the Justice's opinion is what Congress did.

    The dissent illustrates the significance of where the burden is placed on convincing the Court with earlier cases:  here, the dissent contends that the majority was "unable to identify a single case—not one—from any court of ap­peals sitting in law or in equity before the merger, or sitting after the merger but before 1952 holding that laches could not bar a patent claim for damages."  Of course the majority considered the converse, that Respondents and amici did not show sufficient cases that laches could provide such a bar.  And the Justice notes that every Court of Appeals case considering the question since enactment of the 1952 Patent Act had found that laches can bar damages claims, contrary to the majority's decision.

    The dissent also distinguished Petrella, relying on legal as well as practical differences between patent and copyright.  And the dissent ends with an aphorism ironic in view of the pen that has written it:

    [T]he majority remains "determined to stay the course and continue on, travelling even further away," Mathis v. United States, 579 U. S. ___, ___ (2016) (ALITO J., dissenting) (slip op., at 9), from Congress' efforts, in the Patent Act, to promote the "Progress of Science and useful Arts," U. S. Const., Art. I, §8, cl. 8.  Trite but true: Two wrongs don't make a right.

    SCA Hygiene Products Aktiebolag v. First Quality Baby Products, LLC (2017)
    Opinion of the Court by Justice Alito, joined by Chief Justice Roberts and Justices Kennedy, Thomas, Ginsburg, Sotomayor, and Kagan;
    Dissenting opinion by Justice Breyer

  • By John Cravero and Richard Martin

    USPTO SealAbout the PTAB Life Sciences Report:  Each month we will report on developments at the PTAB involving life sciences patents.

    Smith & Nephew, Inc. v. ConforMIS, Inc.

    PTAB Petition:  IPR2017-00510; filed December 20, 2016.

    Patent at Issue: U.S. Patent No. 7,981,158 ("Patient selectable joint arthroplasty devices and surgical tools," issued July 19, 2011) claims methods of generating, making, designing, and using a patient-matched surgical tool.

    Petitioner Smith & Nephew, Inc. is challenging the '158 patent on four grounds as obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '158 patent is the subject of a litigation captioned ConforMIS, Inc. v. Smith & Nephew, Inc., No. 1:16-cv-10420- IT (D. Mass.).  Also, Petitioner is filing a petition concurrently for inter partes review of the '158 patent (IPR2017-00511).


    Smith & Nephew, Inc. v. ConforMIS, Inc.

    PTAB Petition:  IPR2017-00511; filed December 20, 2016.

    Patent at Issue:  U.S. Patent No. 7,981,158 ("Patient selectable joint arthroplasty devices and surgical tools," issued July 19, 2011) claims methods of generating, making, designing, and using a patient-matched surgical tool.

    Petitioner Smith & Nephew, Inc. is challenging the '158 patent on two grounds as obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '158 patent is the subject of a litigation captioned ConforMIS, Inc. v. Smith & Nephew, Inc., No. 1:16-cv-10420- IT (D. Mass.).  Also, Petitioner is filing a petition concurrently for inter partes review of the '158 patent (IPR2017-00510).


    Lexion Medical LLC. v. SurgiQuest, Inc.

    PTAB Petition:  IPR2017-00518; filed December 21, 2016.

    Patent at Issue:  U.S. Patent No. 9,095,372 ("System and method for improved gas recirculation in surgical trocars with pneumatic sealing," issued August 5, 2015) claims a system for insufflation and recirculation of insufflation fluid in a surgical procedure.

    Petitioner Lexion Medical LLC is challenging the '372 patent on one ground as obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '372 patent is the subject of litigation captioned ConMed Corporation et al. v. Lexion Medical LLC., No. 6:16-cv-944-DNH/ATB (E.D. NY.).


    Smith & Nephew, Inc. v. ConforMIS, Inc.

    PTAB Petition:  IPR2017-00544; filed December 27, 2016.

    Patent at Issue:  U.S. Patent No. 7,534,263 ("Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty," issued May 19, 2009) claims tools and methods of making tools for repairing articular surfaces repair materials and for repairing an articular surface.

    Petitioner Smith & Nephew, Inc. is challenging the '263 patent on five grounds as obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '263 patent is the subject of a litigation captioned ConforMIS, Inc. v. Smith & Nephew, Inc., No. 1:16-cv-10420- IT (D. Mass.).  Also, Petitioner is filing a petition concurrently for inter partes review of the '263 patent (IPR2017-00545).


    Smith & Nephew, Inc. v. ConforMIS, Inc.

    PTAB Petition:  IPR2017-00545; filed December 27, 2016.

    Patent at Issue:  U.S. Patent No. 7,534,263 ("Surgical tools facilitating increased accuracy, speed and simplicity in performing joint arthroplasty," issued May 19, 2009) claims tools and methods of making tools for repairing articular surfaces repair materials and for repairing an articular surface.

    Petitioner Smith & Nephew, Inc. is challenging the '263 patent on five grounds as obvious under 35 U.S.C. § 103(a).  View the petition here.

    Related Matters:  According to the petition, the '263 patent is the subject of a litigation captioned ConforMIS, Inc. v. Smith & Nephew, Inc., No. 1:16-cv-10420- IT (D. Mass.).  Also, Petitioner is filing a petition concurrently for Inter Partes Review of the '263 patent (IPR2017-00544).


    Kaz USA, Inc. v. Exergen

    PTAB Petition:  IPR2016-01186; filed July 14, 2016.

    PTAB Trial Instituted Document filed December 27, 2016.

    Patent at Issue:  U.S. Patent No. 7,346,386 ("Temporal artery temperature detector," issued March 18, 2007) claims a body temperature detector.

    Petitioner KAZ USA, Inc. is challenging the '386 patent on six grounds as being anticipated under 35 U.S.C. § 102(b) (ground 1) or obvious under 35 U.S.C. § 103(a) (grounds 2 through 6).  View the petition here.  Administrative Patent Judges Phillip J. Kauffman (author), Meredith C. Petravick, and William V. Saindon issued a decision instituting inter partes review of claims 1 and 2 as being anticipated under 35 U.S.C. § 102(b) by Pompei '813; claims 3, 4, 22, and 24 as obvious under 35 U.S.C. § 103(a) over Pompei '813 and Pompei '091; claims 1 and 2 as obvious under 35 U.S.C. § 103(a) over Banke and Houdas; and claims 3, 4, 22, and 24 as obvious under 35 U.S.C. § 103(a) over Banke, Houdas, and Pompei '091.

    Related Matters:  According to the petition, the '386 patent is involved in the litigation captioned Exergen Corp. v. Microlife Corp. et al., No. 1:15-cv-13387 (D. Mass).

  • By Donald Zuhn

    Federal Circuit SealEarlier this month, in Bayer CropScience AG v. Dow Agrosciences LLC, the Federal Circuit concluded that the District Court for the Eastern District of Virginia correctly confirmed an international arbitration tribunal's award of $455 million, modified the judgment such that post-judgment interest accrues at the federal statutory rate, and affirmed the judgment as modified.

    At the center of the dispute between Bayer CropScience NV and Bayer CropScience AG ("Bayer") and Dow Agrosciences LLC, Mycogen Plant Science, Inc., Agrigenetics, Inc., and Phytogen Seed Co. ("Dow") was a 1992 cross-licensing agreement between Hoechst AG (Bayer's predecessor) and Lubrizol Genetics, Inc. (Dow's predecessor), in which Hoechst granted Lubrizol Genetics licenses to the Leemans patent family (which describes and claims various technologies related to the pat gene, which confers resistance to the herbicide glufosinate) and the Strauch patent family.  Bayer CropScience NV now owns or co-owns the Leemans patent family as a successor of Plant Genetic Systems NV.  Bayer CropScience AG owns the Strauch patent family as a successor of Hoechst AG.  Article 4 of the 1992 agreement restricted the parties' use of the licensed technology, and Article 12 of the 1992 agreement stated that the agreement was to be governed by and construed in accordance with French law and that disputes were to be decided by arbitration in accordance with the Rules of Conciliation and Arbitration of the International Chamber of Commerce.

    Dow AgroSciences LLC produces the Enlist E3, Enlist E3+IR, Enlist Soybean, Enlist Cotton, Widestrike, and Widestrike 3 products, each of which contains the pat gene, through its subsidiaries, Mycogen Plant Science, Inc., Agrigenetics, Inc., and Phytogen Seed Co.  Between 2007 and 2008, Dow entered into a series of agreements with MS Technologies, LLC regarding the pat gene, and this collaboration resulted in the creation of the Enlist E3 products.

    In 2012, Bayer terminated the 1992 agreement with Dow, accusing Dow of materially breaching Article 4 of the agreement.  Bayer then sued Dow for infringement of several patents involved in the 1992 agreement.  Dow moved to dismiss or stay the action based on Article 12 of the agreement, and the District Court stayed the action.  Dow also filed six requests for inter partes reexamination of several patents involved in the 1992 agreement and one reissue patent corresponding to a patent involved in the agreement, alleging inter alia that certain claims of the patents were invalid for obviousness-type double patenting over two of the Strauch patents and a third patent.  (The opinion notes that the inter partes reexaminations remain pending before the U.S. Patent and Trademark Office and did not alter the Court's resolution of the appeal.)

    In 2015, an arbitral tribunal entered an award, finding that (1) Dow breached the 1992 agreement by effectively sublicensing the pat gene to MS Tech; (2) Dow infringed various claims of the Leemans patents by its creation and other activities involving the Enlist and Widestrike products; (3) certain asserted claims were not invalid for inadequate written description or lack of enablement; and (4) certain asserted patents were not invalid for obviousness-type double patenting over the Strauch patent.  The tribunal awarded Bayer $455,459,187 in damages, including $374,731,000 in lost-opportunity damages under French law for breach of contract and $67,837,000 in reasonable-royalty damages under U.S. law for patent infringement, and also awarded Bayer pre-award interest using a rate of 8% and declared that the same rate would apply to "post-award interest."

    Bayer moved the District Court to confirm the arbitral award, and Dow cross-moved to vacate the award.  Dow also moved to amend the judgment such that post-judgment interest would accrue at the rate specified by 28 U.S.C. § 1961(a) and not at the tribunal's 8% rate for "post-award interest."  The District Court confirmed the arbitral award and denied Dow's motion to amend the judgment, and Dow appealed to the Federal Circuit.

    The Federal Circuit, after concluding that it had jurisdiction under 28 U.S.C. § 1295(a)(1), turned to the arbitral award, stating that:

    Judicial review of the arbitral award at issue here is very limited even if, as we assume for present purposes, the standards governing both international and domestic arbitration apply.  In numerous ways, the relevant federal statutes and precedents make clear that ordinary legal or factual error is not a ground for disturbing an arbitral award like the one at issue here.

    The Court also noted that "[a] challenger must meet related, and similarly high, standards to support a refusal to confirm an award as contrary to public policy."

    In view of the strict limits for disturbing an arbitral award, the Federal Circuit rejected Dow's arguments attacking the arbitral award as counter to U.S. law or policies governing double patenting and post-patent-expiration royalties.  With respect to Dow's double patenting argument, the Federal Circuit stated that "[t]he tribunal carefully scrutinized Dow's argument," and "concluded that the patents were not commonly owned because Bayer CropScience AG and Bayer CropScience NV were different entities and Dow had not provided sufficient evidence to pierce the corporate veil separating them."  The Court also rejected Dow's argument that the tribunal's contract-damages award is partially unenforceable because it violates U.S. patent law limits on the recovery of post-expiration royalties for practicing a patent, determining that:

    Under the standards for public-policy and manifest-disregard challenges, we conclude, Dow has not established that the contract award—more precisely, the portion of the award reaching past the 2023 expiration of the RE’962 reissue patent—must be vacated based on Brulotte.

    The Court noted that in Brulotte v. Thys Co., 379 U.S. 29 (1964), the Supreme Court held unenforceable a licensing agreement that required the licensee to pay royalties after the expiration of the patent.

    The Federal Circuit also rejected a number of other arguments presented by Dow for vacating the arbitral award, including the arbitral tribunal's (1) rejection of Dow's written description and enablement defenses, (2) ruling on Bayer's reissue patent, (3) misconstruction of relevant contract provisions, and (4) imposition of an 8% rate for pre-award interest.  With respect to Dow's written description and enablement defenses, the Court noted that "its arguments amount to no more than allegations of ordinary legal error," and determined that "[t]he tribunal's analysis shows no manifest disregard of law or other error meeting the standards for rejection of arbitral determinations."  The Court also determined that none of Dow's other arguments warranted vacating the arbitral award.

    Although the Federal Circuit affirmed the District Court's decision to confirm the arbitral award, the Federal Circuit concluded that the District Court abused its discretion in denying Dow's motion to amend the judgment to use the federal statutory rate for post-judgment interest for the period beginning with the entry of the District Court's judgment.  The Federal Circuit therefore exercised its discretion under 28 U.S.C. § 2106 to "affirm, modify, vacate, set aside or reverse any judgment, decree, or order of a court lawfully brought before it for review," and modified the District Court's judgment to include the relief requested by Dow's motion to amend (i.e., post-judgment interest accruing from the date on which the District Court entered judgment at the rate established in § 1961).  The Federal Circuit then affirmed the judgment as modified.

    Bayer CropScience AG v. Dow Agrosciences LLC (Fed. Cir. 2016)
    Nonprecedential disposition
    Panel: Circuit Judges Moore, Taranto, and Chen
    Opinion by Circuit Judge Taranto